On November 5, 2020 ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, reported a business and financial update (Press release, ERYtech Pharma, NOV 5, 2020, View Source [SID1234570079]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TRYbeCA-1 Phase 3 trial in second-line metastatic pancreatic cancer
NOPHO-sponsored Phase 2 trial in acute lymphoblastic leukemia
Appointment of Dr. Stewart Craig as Chief Technical Officer
Cash and cash equivalents of €40.5 million ($47.5 million) at the end of September 2020
€10 million ($11.7 million) in non-dilutive financing secured in the form of state-guaranteed loans